Table 4 Comparison of the reasons for discontinuation between neoplasms and non-neoplasms trials

 Commercial or strategic decision ^b

13 (16.9)

71 (30.2)

0.022^c

 Lack of funding

1 (1.3)

6 (2.6)

1.000^d

 Trial exemption

1 (1.3)

6 (2.6)

1.000^d

 Protocol issues ^b

10 (13.0)

31(13.2)

0.963^c

 Poor recruitment ^b

16 (20.8)

19 (8.1)

0.002^c

 Inadequate supplies

0 (0)

9 (3.8)

0.119^d

 Study centre availability

0 (0)

11 (4.7)

0.072^d

 Experimental conditions failed to meet requirements

1 (1.3)

3 (1.3)

1.000^d

 Good laboratory or clinical practice

1 (1.3)

9 (3.8)

0.460^d

 Poor compliance of volunteers

0 (0)

2 (0.9)

1.000^d

 Insufficient preparation

2 (2.6)

9 (3.8)

1.000^d

 Poor management ability of the principal investigator

0 (0)

2 (0.9)

1.000^d

 Futility/lack of efficacy ^b

22 (28.6)

48 (20.4)

0.137^c

 Safety

9 (11.7)

12 (5.1)

0.045^c